Navigation Links
Magnetic probe successfully tracks implanted cells in cancer patients

By using MRI to detect magnetic probes of tiny iron oxide particles, an international research team for the first time has successfully tracked immune-stimulating cells implanted into cancer patients for treatment purposes.

"In four of the eight patients, MRI revealed that the implanted cells weren't where they needed to be to be effective for treatment," says Jeff Bulte, Ph.D., an associate professor of radiology at Hopkins' Institute for Cell Engineering who developed methods to optimally label cells with the clinically approved iron oxide particles.

This new application of the probes -- already clinically approved for MRI scanning of the liver -- could dramatically improve efforts to test and use cellular therapies such as vaccines to treat cancer or prevent its recurrence or stem cells to repair damaged organs, say the researchers.

Bulte and a team of Dutch researchers used MRI and a magnetic probe approved by both European and U.S. agencies to locate therapeutic cells injected into eight melanoma patients.

"Our results show that the MRI-based technique was more accurate than tracking the cells using radioactivity and that ultrasound failed to accurately guide injection of the cells into lymph nodes in half of the patients," says Bulte, an author on the report, which appears in the November issue of Nature Biotechnology.

The cells used in the current study, so-called dendritic cells, are the immune system's own "most wanted posters" because they take up and display foreign proteins that tell the immune system's fighters what cells to look for and destroy.

Since the mid-1990s, clinical trials have been testing dendritic cells to see whether they can stimulate the immune system to kill cancer cells. In these trials, dendritic cells from patients are exposed to proteins from the patients' cancer cells and then returned to the patients.

However, some of the clinical trials of such "cancer vaccines" have bee
'"/>

Source:Johns Hopkins Medical Institutions


Page: 1 2 3

Related biology news :

1. Magnetic system could be key to surgery without scars
2. Magnetic computer sensors may help study biomolecules
3. UCSB scientists probe sea floor venting to gain understanding of early life on Earth
4. Self-assembled nano-sized probes allow Penn researchers to see tumors through flesh and skin
5. Products containing specific probes for detecting alternative splice forms protected
6. Duke engineers develop new 3-D cardiac imaging probe
7. Agilent Technologies releases probe sequence, annotation information for all its commercial gene expression microarrays
8. A probe, not an echo
9. NASA probe could reveal comet life, scientists claim
10. Montreal researchers probe the genetic basis of memory
11. MBL researchers probe how an ancient microbe thrives and evolves without sex

Post Your Comments:
(Date:11/30/2009)..., N.J. - The inaugural Global Conference on Syste...2009, in Washington, DC, focuses on the convergenc...f critical importance to society. , The goal...arch activity around targeted complex systems, exa...s topic includes Critical Infrastructure Systems, ...
(Date:11/30/2009)... obstacle to HIV research is the virus,s exquisite...cientists, traditional tools, like the humble lab ...a team of researchers writing in BioMed Central,s ...nious assault on this problem by creating a mouse ...ng infected with HIV. , George Kassiotis, from t...
(Date:11/30/2009)... is a colorless and odorless radioactive gas that ...dium is a product of uranium decay and is found in...s, and groundwater as well as building materials, ...ncentration is expressed as the amount of radiatio...ducts in a liter of air; thus the units are picocu...
Breaking Biology News(10 mins):First global conference on systems and enterprises at new Stevens location, Washington, DC, Dec. 3-4 2A reductionist approach to HIV research 2Health Physics Society recommends considering action for indoor radon below current guidelines 2Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis 28PMO 29 13216 1Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis 28PMO 29 13216 2Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis 28PMO 29 13216 3Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis 28PMO 29 13216 4Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis 28PMO 29 13216 5Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis 28PMO 29 13216 6Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis 28PMO 29 13216 7Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 1Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 2Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 3Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 4Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 5Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 6Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 7Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 8Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 9Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 10Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 11Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 12Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 13Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 14Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 15Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 16Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 17Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 18Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 19Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 20Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 21Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 22Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 23Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 24Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 25Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 26Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 27Safe Ozone Levels May Not Be for Some 52829 1Safe Ozone Levels May Not Be for Some 52829 2
...ts have combined two molecules that occur naturall...es solar energy to split water into hydrogen and o...l of the American Chemical Society. , This molecu...hydrogen gas, providing an alternative to electrol...o its constituent parts. The breakthrough may pave...
...t real-data study of sharks harvested for their va...many as 73 million sharks are killed each year wor...nally by the United Nations, according to a paper ...dition of Ecology Letters. , "The shark fin trade...nto fin auction records and convert from fin sizes...
...ts and medical researchers for the first time have...measures in real time the level of damage to the s...ts suggest that women,s skin ages faster than men,...s Letters, a journal of the Optical Society of Ame... fabric of the deeper layers of the skin, combinin...
Other Biology News:Genetically engineered blood protein can be used to split water into oxygen and hydrogen 2Triple threat: World fin trade may harvest up to 73 million sharks per year 2German researchers develop first non-invasive test to measure skin aging 2German researchers develop first non-invasive test to measure skin aging 3
(Date:11/30/2009)... , COLUMBUS, Ohio, Nov. 30 The...or one of the nation,s first minority business ear...n Cleveland December 3, is called "Transforming th...iness Early-Stage Capital Summit." It will feature...nority business leaders and local minority entrepr...
(Date:11/30/2009)... , KING OF PRUSSIA, Pa., Nov. 30 /PRNew... company specializing in interactive marketing se...today announced the launch of its HATCH Consultin.../hatch ). Aligning strategic experts across a ran...ing, the HATCH Consulting team is committed to gui...
(Date:11/30/2009)... , NEW YORK, Nov. 30 /PRNewswire-USNewswire/ -...search (MJFF) today announced $1.5 million in tota...potentially disease-modifying therapies for Parkin...Novel Approaches to Drug Discovery for Parkinson,s...lan Corporation, plc (NYSE: ELN ), a neuroscienc...
(Date:11/30/2009)... , BRIARCLIFF MANOR, N.Y., Nov. 30 /PRNew...y guidance document for the publication of company...line today by the British Medical Journal (BMJ). "...on of the importance of providing support and guid...cation of study results in the peer-reviewed medic...
Breaking Biology Technology:Ohio Capital Fund Announces Sponsorship of Minority Business Conference 2Cadient Interactive Announces the Launch of HATCH Consulting Services 2Cadient Interactive Announces the Launch of HATCH Consulting Services 3The Michael J. Fox Foundation Announces $1.5 Million in Funding to Advance Development of Drug Targets for Disease-Modifying Parkinson's Disease Treatments 2The Michael J. Fox Foundation Announces $1.5 Million in Funding to Advance Development of Drug Targets for Disease-Modifying Parkinson's Disease Treatments 3ISMPP Announces Publication of Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP2 Guidelines Published in the BMJ 2ISMPP Announces Publication of Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP2 Guidelines Published in the BMJ 3
...eb. 11 Caliper Life,Sciences, Inc. (Nasdaq: CALP...utsche Bank 2008 Small and Mid Cap Growth Conferen..., February 13 at 4:40 p.m. EST. Kevin,Hrusovsky, P...update on the,company,s business. The live webcast...reye/confLobby.zhtml?ticker=CALP&item_id=17485 ,73...
...s Potential New Short-Course Treatment Option for ...luding MRSA, CAMBRIDGE, Mass., Feb. 11 Targanta,...d today that it has,submitted a New Drug Applicati...(FDA) for its lead antibiotic candidate, oritavanc...otic candidate with potent,bactericidal (killing) ...
...e real-world clinical data on the PROMUS(TM) Stent...ration (NYSE: BSX ) today announced that the firs...(TM), ENdeavor(R) and CYpher(R)) European,registry...Olimus,-eluting,coronary stents. It will collect r...ic,s PROMUS(TM) Everolimus-Eluting Coronary Stent ...
Other Biology Technology:Targanta Submits Oritavancin New Drug Application 2Targanta Submits Oritavancin New Drug Application 3Targanta Submits Oritavancin New Drug Application 4Boston Scientific Announces Start of Major European Registry Assessing Different Olimus-Eluting Stents 2Boston Scientific Announces Start of Major European Registry Assessing Different Olimus-Eluting Stents 3Boston Scientific Announces Start of Major European Registry Assessing Different Olimus-Eluting Stents 4
Rabbit Anti-Methionine Aminopeptidase 2 Polyclonal Antibody, Unconjugated from Abcam
Anti-FKHR, phospho (Thr24) / FKHRL1, phospho (Thr32) Antibody, Unconjugated from Cell Signaling Technology
Mouse Anti-Ricin communis Monoclonal Antibody, Unconjugated, Clone CP23 from Abcam
Kinase Buffer (10X) from Cell Signaling Technology
Biology Products: